Outlook Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Year Ending	TTM	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	2018 - 2014
Net Income	-159.13	-58.98	-66.05	-53.16	-48.87	-36.04	Upgrade
Depreciation & Amortization	0.08	0.04	0.2	0.26	0.55	3.36	Upgrade
Share-Based Compensation	5.35	5.55	7.71	4.89	2.81	1.31	Upgrade
Other Operating Activities	95.44	10.42	1.46	-6.24	0.09	-2.44	Upgrade
Operating Cash Flow	-58.26	-42.97	-56.67	-54.25	-31.79	-32.29	Upgrade
Capital Expenditures	0	0	0	0	0	-0.44	Upgrade
Acquisitions	0	0	0	0	-0.9	0	Upgrade
Investing Cash Flow	0	0	0	0	-0.9	-0.44	Upgrade
Share Issuance / Repurchase	61.87	30.02	62.51	49.9	36.57	45.97	Upgrade
Debt Issued / Paid	-0.01	18.94	-2.92	6.3	0.64	-6.94	Upgrade
Financing Cash Flow	61.86	48.97	59.59	56.19	37.21	39.03	Upgrade
Net Cash Flow	3.6	6	2.92	1.94	4.52	6.3	Upgrade
Free Cash Flow	-58.26	-42.97	-56.67	-54.25	-31.79	-32.73	Upgrade
Free Cash Flow Margin	-	-	-	-	-	-401.75%	Upgrade
Free Cash Flow Per Share	-4.08	-3.44	-5.34	-7.11	-8.76	-35.98	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).